Jemonda-M 500 Tablet ER is a combination oral antidiabetic medication containing Dapagliflozin 10 mg and Metformin 500 mg extended-release. It is indicated for the management of type 2 diabetes mellitus, particularly in patients inadequately controlled with diet and exercise alone. Dapagliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, reduces renal glucose reabsorption, promoting glucosuria and thereby lowering plasma glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to improved glycemic control. The extended-release formulation ensures a sustained therapeutic effect, enhancing patient compliance by reducing dosing frequency. Jemonda-M 500 Tablet ER is typically administered once daily with meals to minimize gastrointestinal side effects commonly associated with Metformin. It is essential to monitor renal function prior to and during therapy, as both components are contraindicated in patients with significant renal impairment. Common adverse effects may include urinary tract infections, genital mycotic infections, gastrointestinal disturbances, and rare instances of lactic acidosis. This combination therapy offers a complementary mechanism of action, providing effective glycemic control while potentially aiding in weight reduction and cardiovascular risk mitigation. Patient education on adherence, lifestyle modifications, and regular monitoring is critical to optimize therapeutic outcomes with Jemonda-M 500 Tablet ER.